Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Filgrastim 15Carboplatin 10Ifosfamide 9Doxorubicin 9Cyclophosphamide 9Peripheral Blood Stem Cell Transplantation 7pembrolizumab 6Radiotherapy 6Gemcitabine 6Temozolomide 5Etoposide 5Cisplatin 5Paclitaxel 4Docetaxel 4Amifostine 4aldesleukin 3aflibercept 3Trastuzumab 3Specimen Handling 3Radiosurgery 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Biopsy 3tislelizumab 2sodium thiosulfate 2selinexor 2pazopanib 2palbociclib 2etoposide phosphate 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × resiquimod × Gynecologic × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡